Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Burning Rock BiotechBNR -0.67%61 Net-Net Working Capital is $4.47 as of Mar. 2026. GuruFocus rates BNR with a GF Score™ of 61/100 and a GF Value™ of $7.46 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 79 Medical Diagnostics & Research companies, Burning Rock Biotech ranks better than 89.87% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Burning Rock Biotech's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $4.47.
The industry rank for Burning Rock Biotech's Net-Net Working Capital or its related term are showing as below:
BNR's Price-to-Net-Net-Working-Capital is ranked better than 89.87% of 79
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.98
vs BNR: 1.98
Burning Rock Biotech (NAS:BNR) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Burning Rock Biotech Net-Net Working Capital Related Terms
Burning Rock Biotech Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech Net-Net Working Capital Chart
BNR vs XGN, PRPO, IDXG: Net-Net Working Capital Comparison
For the Diagnostics & Research subindustry, Burning Rock Biotech's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech Price-to-Net-Net-Working-Capital vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $4.47 mean?
Burning Rock Biotech (BNR) has a Net-Net Working Capital of $4.47 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Burning Rock Biotech According to the industry distribution chart, Burning Rock Biotech ranks #8 out of 79 companies in the Medical Diagnostics & Research industry, placing it in the top 10.1%.
Is Burning Rock Biotech's Net-Net Working Capital too high?
Burning Rock Biotech's current Net-Net Working Capital is $4.47. The Medical Diagnostics & Research industry median Net-Net Working Capital is 5.98. Burning Rock Biotech's value of $4.47 is 25.3% below this industry median. Based on the distribution chart, Burning Rock Biotech ranks #8 out of 79 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Burning Rock Biotech has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Net-Net Working Capital compare to XGN and PRPO?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #8 out of 79 companies for Net-Net Working Capital. This places Burning Rock Biotech in the top 10% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 5.98. Burning Rock Biotech's value of $4.47 is 25.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Diagnostics & Research company?
The median Net-Net Working Capital among Medical Diagnostics & Research companies is 5.98, based on 79 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Burning Rock Biotech's current Net-Net Working Capital of $4.47 is 25.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Burning Rock Biotech For the Medical Diagnostics & Research industry, the median Net-Net Working Capital is 5.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current Net-Net Working Capital is $4.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.46, compared to a current price of $8.84 — trading 18.5% above its estimated fair value. The current Net-Net Working Capital is $4.47 and 25.3% below the Medical Diagnostics & Research industry median of 5.98. Burning Rock Biotech's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current Net-Net Working Capital is $4.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (BNR) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of $8.84 is trading 18.5% above its estimated GF Value™ of $7.46.
GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.
Key valuation signals for BNR:
Net-Net Working Capital: $4.47
GF Value™: $7.46 vs. price of $8.84 (18.5% above fair value)
Industry Position: 25.3% below the Medical Diagnostics & Research median (#8 of 79)
No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
61GF Score
Get the complete analysis for BNR
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNR has been successfully added to your 
